Treatment of HCV: Cirrhosis and DAA Failures |
Conferences
eMediNexus Coverage from: 
Treatment of HCV: Cirrhosis and DAA Failures
Dr Paul J Thuluvath, Baltimore,  06 December 2018
Coronavirus Live Count Map India

remove_red_eye 608 Views
COVID-19 Vaccine Updates

Coronavirus Protocols

#Gastroenterology

0 Read Comments                

Treatment-emergent RASs, especially NS5A resistant RASs, are common, and have an impact on SVR when 2-drug DAA regimen with or without ribavirin is used:NS3 RASs progressively disappear and are replaced by wild-type virusNS5A RASs may persist for yearsTesting for RASs is perhaps beneficial if 2-drug regimen with or without ribavirin is used....
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now